Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

PURPOSE: The RAS/RAF/MEK/ERK signaling pathway is critical to the development of colorectal cancers, and KRAS, NRAS, and BRAF mutations foster resistance to radiation. We performed a phase I trial to determine the safety of trametinib, a potent MEK1/2 inhibitor, with 5-fluorouracil (5FU) chemoradiat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Wu, Christina, Williams, Terence M., Robb, Ryan, Webb, Amy, Wei, Lai, Chen, Wei, Mikhail, Sameh, Ciombor, Kristen K., Cardin, Dana, Timmers, Cynthia, Krishna, Somashekar, Arnold, Mark, Harzman, Alan, Abdel-Misih, Sherif, Roychowdhury, Sameek, Bekaii-Saab, Tanios, Wuthrick, Evan J.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7334091/
https://ncbi.nlm.nih.gov/pubmed/32253228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-4193
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars